
Carlo Bastianelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8684869/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The effect of different contraceptive methods on the vaginal microbiome. Expert Review of Clinical Pharmacology, 2021, 14, 821-836.	1.3	11
2	The use of different doses levonorgestrel-releasing intrauterine system (LNG-IUS): real-world data from a multicenter Italian study. European Journal of Contraception and Reproductive Health Care, 2021, , 1-7.	0.6	5
3	Vertical transmission of SARS-CoV-2 infection in early pregnancy: what is the evidence?. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , 1-2.	0.7	1
4	Effects of progestin-only contraceptives on the endometrium. Expert Review of Clinical Pharmacology, 2020, 13, 1103-1123.	1.3	5
5	Pharmacodynamics of combined estrogen–progestin oral contraceptives: 4. Effects on uterine and cervical epithelia. Expert Review of Clinical Pharmacology, 2020, 13, 163-182.	1.3	4
6	Nexplanon Subdermal Implant: Assessment of Sexual Profile, Metabolism, and Bleeding in a Cohort of Italian Women. BioMed Research International, 2019, 2019, 1-6.	0.9	12
7	<p>Uterine fibroids: an update on current and emerging medical treatment options</p> . Therapeutics and Clinical Risk Management, 2019, Volume 15, 157-178.	0.9	46
8	Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation. Expert Review of Clinical Pharmacology, 2018, 11, 1085-1098.	1.3	15
9	Present Role of Hormonal Contraception in Family Planning. Reproductive Medicine for Clinicians, 2018, , 133-147.	0.2	0
10	Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis. Expert Review of Clinical Pharmacology, 2017, 10, 1129-1144.	1.3	22
11	Cryopreservation protocol for human biliary tree stem/progenitors, hepatic and pancreatic precursors. Scientific Reports, 2017, 7, 6080.	1.6	22
12	Pharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism. Expert Review of Clinical Pharmacology, 2016, 10, 315-326.	1.3	32
13	Emergency contraception: a survey of 1773 women. European Journal of Contraception and Reproductive Health Care, 2016, 21, 455-461.	0.6	11
14	Ovarian function during hormonal contraception assessed by endocrine and sonographic markers: a systematic review. Reproductive BioMedicine Online, 2016, 33, 436-448.	1.1	41
15	Observational, prospective, multicentre study to evaluate the effects of counselling on the choice of combined hormonal contraceptives in Italy—the ECOS (Educational COunselling effectS) study. BMC Women's Health, 2015, 15, 69.	0.8	9
16	Mechanism of Action of Ulipristal Acetate for Emergency Contraception: A Systematic Review. Frontiers in Pharmacology, 2015, 6, 315.	1.6	22
17	Transplantation of human fetal biliary tree stem/progenitor cells into two patients with advanced liver cirrhosis. BMC Gastroenterology, 2014, 14, 204.	0.8	49
18	Second-trimester induced abortions in two tertiary centres in Rome. European Journal of Contraception and Reproductive Health Care, 2014, 19, 121-127.	0.6	2

CARLO BASTIANELLI

#	Article	IF	CITATIONS
19	Different Bleeding Patterns with the Use of Levonorgestrel Intrauterine System: Are They Associated with Changes in Uterine Artery Blood Flow?. BioMed Research International, 2014, 2014, 1-6.	0.9	9
20	The Fas/Fas ligand apoptosis pathway underlies immunomodulatory properties of human biliary tree stem/progenitor cells. Journal of Hepatology, 2014, 61, 1097-1105.	1.8	37
21	Selective progesterone receptor modulators: an update. Expert Opinion on Pharmacotherapy, 2014, 15, 1403-1415.	0.9	23
22	Cholangiocarcinoma: increasing burden of classifications. Hepatobiliary Surgery and Nutrition, 2013, 2, 272-80.	0.7	39
23	Use of the levonorgestrel-releasing intrauterine system, quality of life and sexuality. Experience in an Italian family planning center. Contraception, 2011, 84, 402-408.	0.8	37
24	Emergency contraception: presently available formulations and controversies surrounding their use. Expert Review of Obstetrics and Gynecology, 2011, 6, 569-576.	0.4	2
25	Emergency contraception: A review. European Journal of Contraception and Reproductive Health Care, 2008, 13, 9-16.	0.6	27
26	Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opinion on Pharmacotherapy, 2008, 9, 2487-2496.	0.9	24
27	Selective progesterone receptor modulators 2: use in reproductive medicine. Expert Opinion on Pharmacotherapy, 2008, 9, 2473-2485.	0.9	22
28	Selective progesterone receptor modulators 1: use during pregnancy. Expert Opinion on Pharmacotherapy, 2008, 9, 2459-2472.	0.9	19
29	Hormonal contraception: present and future. Drugs of Today, 2008, 44, 905.	0.7	12
30	Contraception: A social revolution. European Journal of Contraception and Reproductive Health Care, 2007, 12, 3-12.	0.6	27
31	Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 1¼g of ethinyl estradiol and 3 mg of drospirenone. Contraception, 2006, 74, 451-457.	0.8	132
32	Contraception Today. Annals of the New York Academy of Sciences, 2006, 1092, 1-32.	1.8	38